Financhill
Buy
63

OCUL Quote, Financials, Valuation and Earnings

Last price:
$11.04
Seasonality move :
-5.62%
Day range:
$10.76 - $11.31
52-week range:
$5.79 - $11.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
30.99x
P/B ratio:
6.61x
Volume:
2.1M
Avg. volume:
2.8M
1-year change:
45.13%
Market cap:
$1.8B
Revenue:
$63.7M
EPS (TTM):
-$1.15

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
OCUL
Ocular Therapeutix
$13.1M -$0.36 -20.3% -33.34% $17.92
AXSM
Axsome Therapeutics
$139.8M -$1.04 61.04% -35.15% $176.79
CADL
Candel Therapeutics
-- -$0.18 -- -77.03% $22.60
RXRX
Recursion Pharmaceuticals
$16.2M -$0.35 12.7% -11% $7.14
SPRO
Spero Therapeutics
-- -$0.32 -100% -3.03% $5.00
TGTX
TG Therapeutics
$145.3M $0.28 101.13% 653.48% $40.50
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
OCUL
Ocular Therapeutix
$11.03 $17.92 $1.8B -- $0.00 0% 30.99x
AXSM
Axsome Therapeutics
$108.98 $176.79 $5.4B -- $0.00 0% 12.18x
CADL
Candel Therapeutics
$5.81 $22.60 $291.1M -- $0.00 0% 1,783.42x
RXRX
Recursion Pharmaceuticals
$5.28 $7.14 $2.1B -- $0.00 0% 27.89x
SPRO
Spero Therapeutics
$2.81 $5.00 $157.1M 10.75x $0.00 0% 5.41x
TGTX
TG Therapeutics
$37.09 $40.50 $5.9B 154.52x $0.00 0% 15.43x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
OCUL
Ocular Therapeutix
20.65% -0.125 5.93% 9.89x
AXSM
Axsome Therapeutics
77.32% 0.872 3.16% 1.90x
CADL
Candel Therapeutics
-- -0.537 -- --
RXRX
Recursion Pharmaceuticals
2.61% 1.448 1.17% 3.85x
SPRO
Spero Therapeutics
-- 10.974 -- 2.51x
TGTX
TG Therapeutics
-- -0.654 -- 2.01x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
OCUL
Ocular Therapeutix
$9.4M -$63.9M -46.82% -56.05% -570.85% -$46.6M
AXSM
Axsome Therapeutics
$111.7M -$55.5M -103.06% -309.19% -46.91% -$43.7M
CADL
Candel Therapeutics
-- -$8.1M -- -- -- -$8.6M
RXRX
Recursion Pharmaceuticals
-$7M -$191.4M -80% -82.61% -1364.13% -$133.8M
SPRO
Spero Therapeutics
-- -$14.6M -108.26% -108.26% -284.8% -$4M
TGTX
TG Therapeutics
$105.3M $8.6M 11.64% 19.78% 10.12% -$28.7M

Ocular Therapeutix vs. Competitors

  • Which has Higher Returns OCUL or AXSM?

    Axsome Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -48.92%. Ocular Therapeutix's return on equity of -56.05% beat Axsome Therapeutics's return on equity of -309.19%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
    AXSM
    Axsome Therapeutics
    91.94% -$1.22 $234.6M
  • What do Analysts Say About OCUL or AXSM?

    Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 62.44%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.79 which suggests that it could grow by 62.22%. Given that Ocular Therapeutix has higher upside potential than Axsome Therapeutics, analysts believe Ocular Therapeutix is more attractive than Axsome Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    6 0 0
    AXSM
    Axsome Therapeutics
    14 0 0
  • Is OCUL or AXSM More Risky?

    Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.459, suggesting its less volatile than the S&P 500 by 54.053%.

  • Which is a Better Dividend Stock OCUL or AXSM?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or AXSM?

    Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. Ocular Therapeutix's net income of -$64.1M is lower than Axsome Therapeutics's net income of -$59.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 30.99x versus 12.18x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    30.99x -- $10.7M -$64.1M
    AXSM
    Axsome Therapeutics
    12.18x -- $121.5M -$59.4M
  • Which has Higher Returns OCUL or CADL?

    Candel Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of --. Ocular Therapeutix's return on equity of -56.05% beat Candel Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
    CADL
    Candel Therapeutics
    -- $0.13 --
  • What do Analysts Say About OCUL or CADL?

    Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 62.44%. On the other hand Candel Therapeutics has an analysts' consensus of $22.60 which suggests that it could grow by 288.99%. Given that Candel Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Candel Therapeutics is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    6 0 0
    CADL
    Candel Therapeutics
    4 0 0
  • Is OCUL or CADL More Risky?

    Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Candel Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock OCUL or CADL?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Candel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Candel Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or CADL?

    Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Candel Therapeutics quarterly revenues of --. Ocular Therapeutix's net income of -$64.1M is lower than Candel Therapeutics's net income of $7.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Candel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 30.99x versus 1,783.42x for Candel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    30.99x -- $10.7M -$64.1M
    CADL
    Candel Therapeutics
    1,783.42x -- -- $7.4M
  • Which has Higher Returns OCUL or RXRX?

    Recursion Pharmaceuticals has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -1366.49%. Ocular Therapeutix's return on equity of -56.05% beat Recursion Pharmaceuticals's return on equity of -82.61%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
    RXRX
    Recursion Pharmaceuticals
    -47.31% -$0.50 $959M
  • What do Analysts Say About OCUL or RXRX?

    Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 62.44%. On the other hand Recursion Pharmaceuticals has an analysts' consensus of $7.14 which suggests that it could grow by 35.28%. Given that Ocular Therapeutix has higher upside potential than Recursion Pharmaceuticals, analysts believe Ocular Therapeutix is more attractive than Recursion Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    6 0 0
    RXRX
    Recursion Pharmaceuticals
    1 6 0
  • Is OCUL or RXRX More Risky?

    Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Recursion Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock OCUL or RXRX?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Recursion Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or RXRX?

    Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than Recursion Pharmaceuticals quarterly revenues of $14.8M. Ocular Therapeutix's net income of -$64.1M is higher than Recursion Pharmaceuticals's net income of -$202.5M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Recursion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 30.99x versus 27.89x for Recursion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    30.99x -- $10.7M -$64.1M
    RXRX
    Recursion Pharmaceuticals
    27.89x -- $14.8M -$202.5M
  • Which has Higher Returns OCUL or SPRO?

    Spero Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of -271.3%. Ocular Therapeutix's return on equity of -56.05% beat Spero Therapeutics's return on equity of -108.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
    SPRO
    Spero Therapeutics
    -- -$0.25 $33.8M
  • What do Analysts Say About OCUL or SPRO?

    Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 62.44%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 77.94%. Given that Spero Therapeutics has higher upside potential than Ocular Therapeutix, analysts believe Spero Therapeutics is more attractive than Ocular Therapeutix.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    6 0 0
    SPRO
    Spero Therapeutics
    0 2 0
  • Is OCUL or SPRO More Risky?

    Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

  • Which is a Better Dividend Stock OCUL or SPRO?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or SPRO?

    Ocular Therapeutix quarterly revenues are $10.7M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Ocular Therapeutix's net income of -$64.1M is lower than Spero Therapeutics's net income of -$13.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 30.99x versus 5.41x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    30.99x -- $10.7M -$64.1M
    SPRO
    Spero Therapeutics
    5.41x 10.75x $5.1M -$13.9M
  • Which has Higher Returns OCUL or TGTX?

    TG Therapeutics has a net margin of -598.74% compared to Ocular Therapeutix's net margin of 4.19%. Ocular Therapeutix's return on equity of -56.05% beat TG Therapeutics's return on equity of 19.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    OCUL
    Ocular Therapeutix
    88.2% -$0.38 $335.1M
    TGTX
    TG Therapeutics
    87.14% $0.03 $237.3M
  • What do Analysts Say About OCUL or TGTX?

    Ocular Therapeutix has a consensus price target of $17.92, signalling upside risk potential of 62.44%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 9.21%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    OCUL
    Ocular Therapeutix
    6 0 0
    TGTX
    TG Therapeutics
    5 1 0
  • Is OCUL or TGTX More Risky?

    Ocular Therapeutix has a beta of 1.431, which suggesting that the stock is 43.081% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

  • Which is a Better Dividend Stock OCUL or TGTX?

    Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios OCUL or TGTX?

    Ocular Therapeutix quarterly revenues are $10.7M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Ocular Therapeutix's net income of -$64.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 154.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 30.99x versus 15.43x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    OCUL
    Ocular Therapeutix
    30.99x -- $10.7M -$64.1M
    TGTX
    TG Therapeutics
    15.43x 154.52x $120.9M $5.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Can FUBO Stock Double?
Can FUBO Stock Double?

TV streaming service Fubo (NYSE:FUBO) has seen incredible returns so…

Where Will CoreWeave Stock Be in 1 Year?
Where Will CoreWeave Stock Be in 1 Year?

When CoreWeave (NASDAQ: CRWV) slipped below its $40 IPO price…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock